The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: CAR-T cell-based compositions. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

CAR-T cell-based compositions are a key innovation area in immuno-oncology

Chimeric Antigen Receptor (CAR)-T cell therapy is a type of cancer immunotherapy that uses genetically engineered T cells for the detection and destruction of cancer cells. CAR-T cell therapy uses modified autologous T-cells to express a CAR specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 230+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of CAR-T cell-based compositions.

Key players in CAR-T cell-based compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to CAR-T cell-based compositions

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
Immatics 2063 Unlock Company Profile
Bristol-Myers Squibb 564 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 355 Unlock Company Profile
Cellectis 301 Unlock Company Profile
Gilead Sciences 237 Unlock Company Profile
Autolus 228 Unlock Company Profile
Fred Hutchinson Cancer Research Center 222 Unlock Company Profile
bluebird bio 212 Unlock Company Profile
City of Hope 194 Unlock Company Profile
ImmunityBio 169 Unlock Company Profile
Iovance Biotherapeutics 150 Unlock Company Profile
Immunovative Therapies 139 Unlock Company Profile
CARsgen Therapeutics 132 Unlock Company Profile
Miltenyi Biotec 122 Unlock Company Profile
CRISPR Therapeutics 121 Unlock Company Profile
Seattle Children's Hospital 120 Unlock Company Profile
Pfizer 102 Unlock Company Profile
BioNTech 89 Unlock Company Profile
Sangamo Therapeutics 89 Unlock Company Profile
Takeda Pharmaceutical 80 Unlock Company Profile
Precision Biosciences 76 Unlock Company Profile
ONK Therapeutics 75 Unlock Company Profile
Allogene Therapeutics 74 Unlock Company Profile
Innovative Cellular Therapeutics 72 Unlock Company Profile
Massachusetts General Hospital 72 Unlock Company Profile
PT Soho Global Health Tbk 71 Unlock Company Profile
Targovax 66 Unlock Company Profile
Io Therapeutics 61 Unlock Company Profile
Eureka Therapeutics 61 Unlock Company Profile
TCR2 Therapeutics 56 Unlock Company Profile
Amgen 55 Unlock Company Profile
F. Hoffmann-La Roche 54 Unlock Company Profile
Nanjing Legend Biotech 53 Unlock Company Profile
United States Of America 52 Unlock Company Profile
Mayo Clinic 50 Unlock Company Profile
Adicet Bio 50 Unlock Company Profile
Editas Medicine 50 Unlock Company Profile
American Gene Technologies International 50 Unlock Company Profile
OncoTherapy Science 50 Unlock Company Profile
Atara Biotherapeutics 47 Unlock Company Profile
AiCuris Anti-infective Cures 46 Unlock Company Profile
CytoImmune Therapeutics 45 Unlock Company Profile
Fate Therapeutics 43 Unlock Company Profile
Genscript Biotech 42 Unlock Company Profile
Tessa Therapeutics 41 Unlock Company Profile
Gracell Biotechnologies 40 Unlock Company Profile
Nkarta 39 Unlock Company Profile
CERo Therapeutics 39 Unlock Company Profile
Hadasit Bio-Holdings 39 Unlock Company Profile
Aleta Biotherapeutics 39 Unlock Company Profile

Source: GlobalData Patent Analytics

Immatics is a leading patent filer of CAR-T cell-based compositions. Its ACTengine programs are based on the genetic engineering of a patient’s own, autologous T cells with novel TCRs designed to recognise the cancer target on the tumour. The company has several assets such as IMA203, IMA201 and IMA204. It is developing TCR-based immunotherapies with an emphasis on treating various solid tumours.

In terms of application diversity, Genscript Biotech is the top company, followed by Turnstone Biologics and GammaDelta Therapeutics. By means of geographic reach, Otsuka holds the top position, while Genscript Biotech and OncoTherapy Science are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.